XW043C7Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

New Technology›Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS XW043C7
CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.FacebookXLinkedInPrint

XW043C7 is a billable ICD-10-PCS procedure code for Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Code Identity

ICD-10-PCS Code
XW043C7
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
Parent Code
XW0
Short Description
Introduce Autolog CAR T in Central Vein, Perc, New Tech 7

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart4Central Vein
5Approach3Percutaneous
6Device/Substance/TechnologyCEngineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
7Qualifier7New Technology Group 7

Code History

Replaces previously assigned code(s):
  • XW043C3 — Introduce Auto CAR T cell in Central Vein, Perc, New Tech 3
Replaced in the FY 2026 code set by:
  • XW0438A — Introduce Obecab Autoleuc in Central Vein, Perc, New Tech 1

Similar Procedure Codes

Questions About XW043C7

Is XW043C7 a billable code?

Yes. XW043C7 is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW043C7 mean?

XW043C7 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character C is the Device/Substance/Technology (Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous); the 7th character 7 is the Qualifier (New Technology Group 7).